Calamos Advisors LLC Regeneron Pharmaceuticals, Inc. Transaction History

Calamos Advisors LLC

  • $16.1 Billion
  • Q3 2024

A detailed history of Calamos Advisors LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Calamos Advisors LLC holds 12,135 shares of REGN stock, worth $8.52 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
12,135
Previous 12,433 2.4%
Holding current value
$8.52 Million
Previous $13.1 Million 2.38%
% of portfolio
0.08%
Previous 0.08%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024
SELL
$1024.09 - $1201.76 $305,178 - $358,124
-298 Reduced 2.4%
12,135 $12.8 Million
Q2 2024

Jul 25, 2024
SELL
$883.2 - $1071.19 $400,972 - $486,320
-454 Reduced 3.52%
12,433 $13.1 Million
Q1 2024

May 08, 2024
SELL
$902.69 - $993.35 $292,471 - $321,845
-324 Reduced 2.45%
12,887 $12.4 Million
Q4 2023

Jan 31, 2024
SELL
$775.18 - $881.7 $134,106 - $152,534
-173 Reduced 1.29%
13,211 $11.6 Million
Q1 2023

May 03, 2023
SELL
$680.49 - $826.97 $1.15 Million - $1.4 Million
-1,687 Reduced 11.19%
13,384 $11 Million
Q4 2022

Jan 25, 2023
SELL
$705.89 - $766.39 $1.88 Million - $2.04 Million
-2,661 Reduced 15.01%
15,071 $0
Q3 2022

Oct 24, 2022
SELL
$573.97 - $724.32 $10,331 - $13,037
-18 Reduced 0.1%
17,732 $12.2 Million
Q2 2022

Aug 01, 2022
BUY
$548.35 - $738.84 $270,336 - $364,248
493 Added 2.86%
17,750 $10.5 Million
Q1 2022

May 03, 2022
BUY
$595.12 - $698.43 $1.38 Million - $1.62 Million
2,315 Added 15.49%
17,257 $12.1 Million
Q4 2021

Feb 01, 2022
BUY
$543.48 - $670.97 $314,131 - $387,820
578 Added 4.02%
14,942 $9.44 Million
Q3 2021

Oct 26, 2021
BUY
$574.03 - $680.96 $727,870 - $863,457
1,268 Added 9.68%
14,364 $8.69 Million
Q2 2021

Jul 22, 2021
BUY
$472.8 - $558.54 $1.41 Million - $1.66 Million
2,979 Added 29.45%
13,096 $7.32 Million
Q1 2021

Apr 12, 2021
BUY
$446.73 - $548.2 $139,826 - $171,586
313 Added 3.19%
10,117 $4.79 Million
Q4 2020

Jan 27, 2021
SELL
$478.3 - $607.98 $203,277 - $258,391
-425 Reduced 4.15%
9,804 $4.74 Million
Q3 2020

Oct 26, 2020
SELL
$544.75 - $658.21 $496,267 - $599,629
-911 Reduced 8.18%
10,229 $5.73 Million
Q2 2020

Jul 27, 2020
SELL
$493.32 - $643.92 $351,243 - $458,471
-712 Reduced 6.01%
11,140 $6.95 Million
Q1 2020

Apr 28, 2020
SELL
$336.18 - $494.43 $329,120 - $484,046
-979 Reduced 7.63%
11,852 $5.79 Million
Q4 2019

Jan 15, 2020
SELL
$274.13 - $376.51 $57,841 - $79,443
-211 Reduced 1.62%
12,831 $4.82 Million
Q3 2019

Oct 21, 2019
BUY
$273.46 - $318.39 $309,283 - $360,099
1,131 Added 9.5%
13,042 $3.62 Million
Q2 2019

Aug 07, 2019
BUY
$299.6 - $414.82 $74,300 - $102,875
248 Added 2.13%
11,911 $3.73 Million
Q1 2019

Apr 12, 2019
BUY
$372.08 - $439.57 $170,784 - $201,762
459 Added 4.1%
11,663 $4.79 Million
Q4 2018

Jan 24, 2019
BUY
$335.82 - $403.04 $563,505 - $676,301
1,678 Added 17.61%
11,204 $4.19 Million
Q3 2018

Oct 22, 2018
SELL
$351.14 - $408.51 $1.8 Million - $2.09 Million
-5,122 Reduced 34.97%
9,526 $3.85 Million
Q2 2018

Jul 17, 2018
SELL
$284.6 - $344.99 $721,461 - $874,549
-2,535 Reduced 14.75%
14,648 $5.05 Million
Q1 2018

Apr 13, 2018
SELL
$315.82 - $393.78 $32.6 Million - $40.6 Million
-103,083 Reduced 85.71%
17,183 $5.92 Million
Q4 2017

Feb 13, 2018
BUY
$358.63 - $469.95 $18.3 Million - $24 Million
51,044 Added 73.74%
120,266 $45.2 Million
Q3 2017

Oct 25, 2017
BUY
$431.38 - $504.0 $24.8 Million - $29 Million
57,538 Added 492.45%
69,222 $31 Million
Q2 2017

Aug 09, 2017
BUY
N/A
11,684
11,684 $5.74 Million

Others Institutions Holding REGN

# of Institutions
1,534
Shares Held
83.6M
Call Options Held
1.22M
Put Options Held
1.51M
View Full List

About REGENERON PHARMACEUTICALS, INC.

REGN Quotes by TradingView
  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $75.2B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Calamos Advisors LLC Portfolio

Follow Calamos Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Calamos Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Calamos Advisors LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email